Corton Capital’s Moderna MRNA Stock Holding History

Corton Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,216	Closed	-$475K	–	326
2025 Q2	$475K	Buy	+17,216	New	+$453K	0.55%	21
2024 Q2	–	Sell	-7,787	Closed	-$830K	–	659
2024 Q1	$830K	Buy	7,787 +724	+10%	+$73K	0.31%	50
2023 Q4	$702K	Buy	+7,063	New	+$594K	0.22%	103

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Corton Capital's MRNA Position: Q3 2025 in Review

Corton Capital sold out of Moderna (MRNA) in Q3 2025, closing a stake of 17,216 shares — an estimated $475K sold.

Corton Capital first reported a position in MRNA in Q4 2023 and held it in 3 quarters. The position peaked at $830K in Q1 2024. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

Corton Capital reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 17,216 Moderna shares in Q3 2025, an estimated $475K.
Corton Capital first reported a position in Moderna in Q4 2023 and held it in 3 quarters.
Corton Capital's Moderna position peaked at $830K in Q1 2024.
643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.